Lakefront Biotherapeutics NV (LKFT) Balance Sheet

NASDAQ: LKFTAssets, liabilities, debt and equity over 4 years.

LKFT balance sheet, 2025

December 31, 2025 · euros

€3.41B assets = €170.7M liabilities + €3.24B equity

What it owns€3.41BCash & ST investments: €3.00B (88.0%)Cash & ST investments€3.00B · 88%Receivables: €53.2M (1.6%)Inventory: €22.5M (0.7%)Other current: €5.7M (0.2%)PP&E: €80.7M (2.4%)Goodwill & intangibles: €848,000 (0.0%)LT investments: €46.8M (1.4%)Other non-current: €198.7M (5.8%)Other non-current €198.7M=How it is financed€3.41BCurrent liabilities: €152.9M (4.5%)Other LT liabilities: €17.8M (0.5%)Shareholders’ equity: €3.24B (95.0%)Shareholders’ equity€3.24B · 95%

Both columns are drawn to the same scale: what LKFT owns equals what it owes plus shareholders’ equity. Hover a block for its value.

LKFT financial health

Debt / equity0.00
Low leverage · €0.00 of debt for each $1 of equity
Equity / assets95.0%
Equity-funded · of assets funded by shareholders
Cash / debt43,355.7%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

LKFT balance sheet trends, 2022–2025

MetricTrendThenLatestChange
Total assets€4.73B2022€3.41B2025−10.4%/yr
Total liabilities€2.21B2022€170.7M2025−57.4%/yr
Shareholders’ equity€2.53B2022€3.24B2025+8.6%/yr
Cash & short-term investments€4.09B2022€3.00B2025−9.9%/yr
Working capital€3.71B2022€2.93B2025−€787.7M
Shares outstanding65.7M202265.9M2025+0.1%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

LKFT assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

LKFT liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

LKFT debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

LKFT balance sheet in euros

2025202420232022
Assets
Cash & short-term investments€3.00B€3.12B€3.68B€4.09B
Cash & equivalents€87.9M€64.2M€166.8M€508.1M
Short-term investments€2.91B€3.05B€3.52B€3.59B
Receivables€53.2M€32.5M€17.5M€28.2M
Inventory€22.5M€51.2M€74.0M€52.9M
Other current assets€5.7M€138.2M€85.6M€61.7M
Total current assets€3.08B€3.34B€3.86B€4.24B
Property, plant & equipment (net)€80.7M€122.9M€126.3M€154.3M
Goodwill & intangible assets€848,000€234.9M€197.5M€216.2M
Long-term investments€46.8M€253.1M€13.6M€0
Other non-current assets€198.7M€185.4M€158.4M€127.1M
Total assets€3.41B€4.14B€4.36B€4.73B
Liabilities
Accounts payable€32.6M€64.2M€134.7M€133.3M
Short-term debt€1.7M———
Deferred revenue€32,000———
Total current liabilities€152.9M€335.1M€428.2M€522.5M
Long-term debt€0€0€0€0
Lease obligations€6.9M€11.7M€9.6M€21.9M
Other long-term liabilities€17.8M€903.7M€1.13B€1.69B
Total liabilities€170.7M€1.24B€1.56B€2.21B
Shareholders' equity
Common stock & paid-in capital€293.9M———
Retained earnings (deficit)€210.6M−€134.3M−€228.3M−€496.7M
Accumulated other comprehensive income−€5.6M———
Total shareholders' equity€3.24B€2.90B€2.80B€2.53B
Key figures
Total debt€6.9M———
Net cash (debt)€2.99B———
Working capital€2.93B€3.00B€3.43B€3.71B
Tangible book value€3.24B€2.66B€2.60B€2.31B
Shares outstanding65.9M66.1M65.9M65.7M
Current ratio20.159.979.028.11
Quick ratio19.969.408.657.89
Debt / equity0.00———
Equity / assets95.0%70.0%64.2%53.4%

Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported (latest annual report filed December 31, 2025); data from EODHD.

LKFT financial position

At the end of fiscal 2025 (December 31, 2025), Lakefront Biotherapeutics had total assets of €3.4 billion (down 17.6% from a year earlier), total liabilities of €170.7 million and shareholders' equity of €3.2 billion. It held €3.0 billion in cash and short-term investments against €6.9 million of debt, a net cash position of €3.0 billion. Its current ratio was 20.15. In the latest quarter (ended June 30, 2026) total assets were €3.3 billion and equity €3.3 billion.

Related: LKFT income statement, LKFT cash flow statement, LKFT key metrics. See the LKFT stock overview for the latest quote and news.

LKFT balance sheet FAQ

What are Lakefront Biotherapeutics's total assets?

Lakefront Biotherapeutics reported total assets of €3.4 billion at the end of fiscal 2025 (December 31, 2025), compared with €4.1 billion a year earlier.

How much debt does Lakefront Biotherapeutics have?

Lakefront Biotherapeutics had €6.9 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.

How much cash does Lakefront Biotherapeutics have?

Lakefront Biotherapeutics held €3.0 billion in cash and short-term investments at the end of fiscal 2025; with €6.9 million of debt that is net cash of €3.0 billion.

What is Lakefront Biotherapeutics's book value?

Lakefront Biotherapeutics's shareholders' equity (book value) was €3.2 billion at the end of fiscal 2025.

What is Lakefront Biotherapeutics's current ratio?

Lakefront Biotherapeutics had current assets of €3.1 billion and current liabilities of €152.9 million, a current ratio of 20.15 (it can cover its short-term obligations).

How much goodwill does Lakefront Biotherapeutics have?

Lakefront Biotherapeutics carried €0.8 million of goodwill and intangible assets, 0.0% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet